COVID-19 cases, hospitalizations, and deaths all continue to decrease in the United States. According to CDC’s COVID Data Tracker, as of March 16, 2022, 76.7% of the total U.S. population has received at least one dose of a COVID-19 vaccine, and 65.3% has completed their primary series. However, only about half of the booster-eligible population has received a booster dose and is considered up to date on their COVID-19 vaccines.
Two new studies show the effectiveness of COVID-19 vaccines and boosters across periods of three variants of concern (Alpha, Delta, and Omicron). CDC released a study today showing that, among adults hospitalized with COVID-19 during the Delta and Omicron waves, those who received two or three doses of the Pfizer-BioNTech or Moderna vaccine had 90–95% less risk of dying or needing a ventilator compared with adults who were not vaccinated. Protection was highest in adults who received a third COVID-19 vaccine dose. A study published in the British Medical Journalexternal icon found that vaccines gave a high level of protection against hospitalization for all variants, but not as much for Omicron among adults who received only a primary series. However, boosters increased protection against Omicron. The study also showed that hospital patients who were vaccinated had much lower disease severity than patients who were not vaccinated. These studies emphasize the importance of staying up to date with vaccinations—they are our best protection against severe COVID-19 illness. Vaccination is also the safest way to reduce the chance that new variants will emerge. Find a vaccine provider and get your booster dose as soon as you can.*
*People who are moderately or severely immunocompromised have specific COVID-19 vaccine recommendations for the primary series and booster dose due to their different immune response following COVID-19 vaccination. For more information, visit CDC’s website.
COVID Data Tracker’s Cases and Deaths by Vaccination Status tab was updated to include booster dose data for the populations 12-17 years.
COVID Data Tracker’s Vaccination Demographic Trends tab was updated to allow users to select a jurisdiction when viewing the Age Group and Sex tab on the “Booster Vaccination Trends” dashboard.
Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
The Advisory Committee on Immunization Practices’ Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022
COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status — COVID-NET, 14 States, July 2021–January 2022
As of March 16, 2022, the current 7-day moving average of daily new cases (30,040) decreased 16.6% compared with the previous 7-day moving average (36,010). A total of 79,486,762 COVID-19 cases have been reported in the United States as of March 16, 2022.
Currently two variants, Omicron and Delta, are classified as Variants of Concern (VOC) in the United States. CDC Nowcast projections* for the week ending March 12, 2022, estimate the combined national proportion of lineages designated as Omicron to be 100%. There are five lineages designated as Omicron: B.1.1.529, BA.1, BA.1.1, BA.2, and BA.3. COVID Data Tracker shows the proportions of the B.1.1.529 lineage (includes BA.1 and BA.3), the BA.1.1** lineage, and the BA.2 lineage. The predominant Omicron lineage in the United States is BA.1.1. The national proportion of BA.1.1 is projected to be 66.1% (95% PI 60.6-71.1%). B.1.1.529 (BA.1 and BA.3) is projected to be 10.8% (95% PI 9.1-12.8%) and BA.2 is projected to be 23.1% (95% PI 18.6-28.3%). Delta is projected to continue to be 0.0% (95% PI 0.0-0.0%). Omicron is predicted to be 100% in all HHS regions.
*The median time from specimen collection to sequence data reporting is about 3 weeks. As a result, weighted estimates for the most recent few weeks may be unstable or unavailable. CDC’s Nowcast is a data projection tool that helps fill this gap by generating timely estimates of variant proportions for variants that are circulating in the United States. View Nowcast estimates on CDC’s COVID Data Tracker website on the Variant Proportions page.
**For national data, the proportion of BA.1.1 is shown separately. For regional data, the proportion of BA.1.1 is also aggregated with B.1.1.529.
***Historical cases are excluded from daily new cases and 7-day average calculations until they are incorporated into the dataset for the applicable date. Of 482,816 historical cases reported retroactively, 23,220 were reported in the current week and 8,517 were reported in the prior week.
Daily Trends in COVID-19 Cases in the United States Reported to CDC
The U.S. COVID-19 Vaccination Program began December 14, 2020. As of March 16, 2022, 557.6 million vaccine doses have been administered in the United States. Overall, about 254.8 million people, or 76.7% of the total U.S. population, have received at least one dose of vaccine. About 216.8 million people, or 65.3% of the total U.S. population, have been fully vaccinated.* About 96.2 million additional or booster doses have been reported in people who have been fully vaccinated; however, 49.9% of the total booster-eligible population has not yet received a booster dose. As of March 16, 2022, the 7-day average number of administered vaccine doses reported (by date of CDC report) to CDC per day was 249,521, a 17.6% decrease from the previous week.
CDC’s COVID Data Tracker Vaccination Demographic Trends tab shows vaccination trends by age group and by race/ethnicity. As of March 16, 2022, 95.0% of people ages 65 years or older have received at least one dose of vaccine and 88.9% are fully vaccinated. For people ages 5–11 years, only 26.9% are fully vaccinated. For people ages 5 years or older, 81.6% have received at least one dose of vaccine and 69.4% are fully vaccinated. Of the fully vaccinated population, people ages 75 years or older have the highest proportion of additional/booster doses (69.1%) while people ages 12–17 have the lowest proportion (22.5%).
As of March 16, 2022, of all race/ethnicity groups, the Asian non-Hispanic population has the highest proportion that is fully vaccinated (60.2%), and the Black non-Hispanic population has the lowest proportion that is fully vaccinated (41.1%). Of the fully vaccinated population, the Asian non-Hispanic population has the highest proportion of additional/booster doses (66.9%), while the Hispanic/Latino population has the lowest proportion (40.1%).
COVID Data Tracker’s COVID-19 Vaccination Equity tab shows vaccination trends by urban/rural status. As of March 16, 2022, 48.8% of people in rural counties are fully vaccinated, while the range of vaccination coverage in the 4 urban/metro counties ranged from 52.7% (micropolitan) to 66.6% (large central metro).